Infliximab in the treatment of plaque type psoriasis
Rosita Saraceno, Andrea Saggini, Lucia Pietroleonardo, Sergio ChimentiDepartment of Dermatology, University of Rome Tor Vergata, Rome, Viale Oxford 81, Rome, ItalyAbstract: Psoriasis is a chronic and immunomediated skin disease characterized by erythematous scaly plaques. Psoriasis affects approxima...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2009-04-01
|
| Series: | Clinical, Cosmetic and Investigational Dermatology |
| Online Access: | http://www.dovepress.com/infliximab-in-the-treatment-of-plaque-type-psoriasis-a3022 |
| _version_ | 1811246478486667264 |
|---|---|
| author | Rosita Saraceno Andrea Saggini Lucia Pietroleonardo Sergio Chimenti |
| author_facet | Rosita Saraceno Andrea Saggini Lucia Pietroleonardo Sergio Chimenti |
| author_sort | Rosita Saraceno |
| collection | DOAJ |
| description | Rosita Saraceno, Andrea Saggini, Lucia Pietroleonardo, Sergio ChimentiDepartment of Dermatology, University of Rome Tor Vergata, Rome, Viale Oxford 81, Rome, ItalyAbstract: Psoriasis is a chronic and immunomediated skin disease characterized by erythematous scaly plaques. Psoriasis affects approximately 1% to 3% of the Caucasian population. Tumor necrosis factor alpha (TNF-α) is a proinflammatory cytokine that plays a critical role in the pathogenesis of psoriasis. Infliximab is an anti-TNF-α drug widely used for the treatment of plaque type psoriasis and psoriatic arthritis. Controlled clinical trials demonstrated that infliximab is characterized by a high degree of clinical response in moderate to severe plaque psoriasis. Moreover infliximab showed rapid efficacy in nail psoriasis which represents a therapeutic challenge for dermatologists and a relevant source of distress for patients with plaque psoriasis. This anti-TNF-α has an encouraging safety profile, especially as long as physicians are watchful in prevention and early diagnosis of infections and infuse reactions. The efficacy, tolerability and safety profiles suggest infliximab as a suitable anti-psoriatic drug in the long-term treatment of a chronic disease such as plaque-type psoriasis.Keywords: psoriasis, nail psoriasis, infliximab, long-term treatment |
| first_indexed | 2024-04-12T14:55:01Z |
| format | Article |
| id | doaj.art-1cf7e4f58d204c56b0e79f9ea22473fc |
| institution | Directory Open Access Journal |
| issn | 1178-7015 |
| language | English |
| last_indexed | 2024-04-12T14:55:01Z |
| publishDate | 2009-04-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Clinical, Cosmetic and Investigational Dermatology |
| spelling | doaj.art-1cf7e4f58d204c56b0e79f9ea22473fc2022-12-22T03:28:18ZengDove Medical PressClinical, Cosmetic and Investigational Dermatology1178-70152009-04-012009default2737Infliximab in the treatment of plaque type psoriasisRosita SaracenoAndrea SagginiLucia PietroleonardoSergio ChimentiRosita Saraceno, Andrea Saggini, Lucia Pietroleonardo, Sergio ChimentiDepartment of Dermatology, University of Rome Tor Vergata, Rome, Viale Oxford 81, Rome, ItalyAbstract: Psoriasis is a chronic and immunomediated skin disease characterized by erythematous scaly plaques. Psoriasis affects approximately 1% to 3% of the Caucasian population. Tumor necrosis factor alpha (TNF-α) is a proinflammatory cytokine that plays a critical role in the pathogenesis of psoriasis. Infliximab is an anti-TNF-α drug widely used for the treatment of plaque type psoriasis and psoriatic arthritis. Controlled clinical trials demonstrated that infliximab is characterized by a high degree of clinical response in moderate to severe plaque psoriasis. Moreover infliximab showed rapid efficacy in nail psoriasis which represents a therapeutic challenge for dermatologists and a relevant source of distress for patients with plaque psoriasis. This anti-TNF-α has an encouraging safety profile, especially as long as physicians are watchful in prevention and early diagnosis of infections and infuse reactions. The efficacy, tolerability and safety profiles suggest infliximab as a suitable anti-psoriatic drug in the long-term treatment of a chronic disease such as plaque-type psoriasis.Keywords: psoriasis, nail psoriasis, infliximab, long-term treatmenthttp://www.dovepress.com/infliximab-in-the-treatment-of-plaque-type-psoriasis-a3022 |
| spellingShingle | Rosita Saraceno Andrea Saggini Lucia Pietroleonardo Sergio Chimenti Infliximab in the treatment of plaque type psoriasis Clinical, Cosmetic and Investigational Dermatology |
| title | Infliximab in the treatment of plaque type psoriasis |
| title_full | Infliximab in the treatment of plaque type psoriasis |
| title_fullStr | Infliximab in the treatment of plaque type psoriasis |
| title_full_unstemmed | Infliximab in the treatment of plaque type psoriasis |
| title_short | Infliximab in the treatment of plaque type psoriasis |
| title_sort | infliximab in the treatment of plaque type psoriasis |
| url | http://www.dovepress.com/infliximab-in-the-treatment-of-plaque-type-psoriasis-a3022 |
| work_keys_str_mv | AT rositasaraceno infliximabinthetreatmentofplaquetypepsoriasis AT andreasaggini infliximabinthetreatmentofplaquetypepsoriasis AT luciapietroleonardo infliximabinthetreatmentofplaquetypepsoriasis AT sergiochimenti infliximabinthetreatmentofplaquetypepsoriasis |